Zai Lab Limited Stock Price, News & Analysis

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced an extraordinary general meeting (EGM) to be held virtually on March 28, 2022, at 8:00 a.m. Eastern Time. This change is due to COVID-19 restrictions in Shanghai. Shareholders will vote on a proposal for a 1-to-10 share subdivision. Shareholders of record may attend the meeting virtually using a control number found on their proxy materials. The EGM format has been updated, but prior proxy materials remain valid for voting.

Zai Lab Limited (NASDAQ: ZLAB) presented Phase 3 PRIME study results at the Society of Gynecologic Oncology annual meeting, revealing that ZEJULA (niraparib) significantly improved progression-free survival (PFS) in patients with advanced ovarian cancer. The median PFS for niraparib was 24.8 months compared to 8.3 months for placebo. Treatment was well-tolerated, with a low discontinuation rate due to adverse events (less than 7%). This data supports niraparib as a standard maintenance therapy after platinum-based chemotherapy in China.

Zai Lab Limited (NASDAQ: ZLAB) announced the appointment of Josh Smiley as Chief Operating Officer (COO) effective August 1, 2022. With over 26 years of biopharmaceutical experience, he previously held leadership roles at Eli Lilly. CEO Dr. Samantha Du emphasized Smiley's leadership expertise as essential for Zai Lab's growth and operational excellence. His appointment comes during a pivotal time for Zai Lab, with significant opportunities in their pipeline aimed at expanding geographically and diversifying their financial base.

Zai Lab Limited (NASDAQ: ZLAB) reported strong financial growth for 2021, achieving net product revenues of $144.1 million compared to $49.0 million in 2020. Key drivers included a 200% increase in ZEJULA revenue and significant advancements in its product pipeline, including proof of concept for ZL-1102. R&D expenses increased to $573.3 million due to new licensing agreements and clinical trials. The company plans to submit new drug applications and expects substantial revenue growth, projecting peak-year sales of $2.5 to $3 billion by 2030.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that its investigational drug repotrectinib received Breakthrough Therapy Designation from the NMPA for treating ROS1-positive metastatic non-small-cell lung cancer (NSCLC) in patients who haven't received ROS1 TKI treatment. The Phase 1/2 TRIDENT-1 study provided initial data supporting this designation. Repotrectinib targets ROS1 and NTRK mutations and may be the best-in-class therapy, offering hope for patients in need, especially in a region with high lung cancer incidence.

Zai Lab Limited (ZLAB) will announce its financial results for the year ended December 31, 2021, after U.S. market close on March 1, 2022. A conference call and webcast will be held on March 2, 2022, at 8:00 a.m. ET. Participants must register in advance to receive access details. Zai Lab is focused on developing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience. The company aims to innovate and commercialize products addressing unmet medical needs globally.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced their participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 8:40 a.m. ET. This virtual investor conference will feature a fireside chat with company management.

Investors can access the live webcast and an archived replay for 90 days on Zai Lab's website under the “Events & Presentations” section. Zai Lab focuses on developing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience while building partnerships to enhance their global biopharmaceutical pipeline.

Zai Lab Limited (NASDAQ: ZLAB) announced the treatment of the first patient in Greater China in the PANOVA-3 trial. This pivotal Phase 3 trial investigates Tumor Treating Fields for pancreatic cancer, a highly aggressive cancer with a low five-year survival rate of about 7% in China. The trial will enroll approximately 556 patients, focusing on overall survival and various secondary endpoints. Given the urgent need for effective treatments, the promising results of Tumor Treating Fields previously approved for other cancers highlight the potential impact on patient outcomes.

Zai Lab Limited (NASDAQ: ZLAB) announced the acceptance of its New Drug Application (NDA) in China for margetuximab, a monoclonal antibody targeting HER2, aimed at treating adult patients with metastatic HER2-positive breast cancer who have undergone prior anti-HER2 therapies. This marks Zai Lab's sixth NDA acceptance by the China National Medical Products Administration (NMPA). The NDA is supported by positive results from the SOPHIA trial, showing improved progression-free survival compared to trastuzumab. Margetuximab has been previously approved by the FDA in the U.S. in 2020.